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To identify, appraise and synthesize the available evidence on two-stage revision hip 
arthroplasty with or without the use of an interim spacer for managing late prosthetic infection. 
The review methodology was designed by referencing the PRISMA checklist and flow diagram, 
and a PICOS framework (Population, Intervention, Comparator, Outcomes and Study designs) 
was used to search for studies to incorporate within the review. Two independent investigators 
were involved in searching for relevant articles that fulfilled the inclusion criteria for the study. 
Critical appraisal of the selected articles was carried out using the relevant Critical Appraisal 
Skills Programme checklists. From an initial pool of 125 articles, four studies satisfied the 
inclusion criteria and quality assessment and were included for final review. Two patient groups 
were identified from within the selected studies – spacer and non-spacer; both groups were 
assessed in terms of functional outcome, infection cure rates and technical difficulties 
encountered during treatment. Better functional outcome was reported in the spacer group, 
both in the interim period between the two stages, and after completion of treatment. The use 
of spacers reduced operative difficulty during the second stage and accelerated patient 
discharge. Reinfection and infection persistence rates were higher in the non-spacer group. 
Within the spacer group, articulated spacers performed better in all parameters. The results of 
this review reinforce the available evidence supporting the use of interim hip spacers in revision 
hip arthroplasty for prosthetic infection, and also indicate that articulated hip spacers could be 
an attractive option going forward.  
 





A two-stage revision hip arthroplasty is a popular approach in the treatment of late infection 
after total hip replacement1,2. Following an initial operation to remove the infected prosthesis, 
the hip is either left with a temporary implanted spacer device, or in a situation like a Girdlestone 
arthroplasty3 for a period ranging from a few weeks to a few months. Systemic targeted 
antibiotic therapy is maintained during this period. Once infection is cured and local soft tissue 
condition is settled, reimplantation of the definitive prosthesis is undertaken as the second stage 
procedure.  
Antibiotic-loaded cement spacers are a popular choice among orthopedic surgeons2,4,5. They are 
reported to provide a formidable local antimicrobial effect by eluting antibiotics, that are mixed 
with the cement, into the soft tissues around the hip6. The presence of the spacer device also 
appears to help preserve some functionality in the hip and reduces the amount of soft tissue 
scarring and contractures, thereby facilitating an easier second operation7. 
In contrast, while good infection cure rates have been reported without spacer use8,9, functional 
outcomes are often poor and rates of complications high. For example, shortening of the leg, 
persistent limp and hip instability have been documented2,8. Further, soft tissue scarring and 
blurring of tissue planes, tissue contractures, and osteoporosis due to inactivity are reported to 
significantly increase the technical difficulty of reimplanting the definitive prosthesis during the 
second stage procedure10.  
There are very few studies that directly compare the technical aspects and treatment outcomes 
of the above two strategies. While the benefits of spacer use are much celebrated, it is worth 
considering that reinfection or persistence of infection following hip spacer implantation can 
lead to higher revision surgery rates and increase overall rates of morbidity and mortality11.  
Moreover, spacers are associated with their own unique set of complications. Monoblock 
spacers are linked with spacer fractures and bone resorption, while two-part spacers can 
generate abraded cement particles and occasionally, dislocate10,12. Systemic complications such 
as allergic reactions to the spacer component, or even hepatic or renal failure have also been 
reported10,11.  
This systematic review aimed to identify, appraise and synthesize the evidence on two-stage 
revision hip arthroplasty with or without the use of an interim spacer for managing late 
prosthetic infection. The following outcomes of interest were assessed in the two groups: 
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1. The functional outcome in the patient groups, both in the interim period between the 
two stages and following the second-stage procedure. 
2. The technical difficulties encountered, and complications, if any, during each stage of 
surgery. 
3. The overall infection eradication rates. 
Methods 
The review methodology was designed by referencing the PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta-analyses) checklist and flow diagram13. 
Inclusion Criteria for Studies 
A PICOS framework (Population, Intervention, Comparator, Outcomes and Study designs)14 was 
used to search for studies to incorporate within the review. Accordingly, the following inclusion 
criteria were identified: 
Population - The population of interest included all patients who had undergone a two-stage 
revision hip arthroplasty for prosthetic hip infection.  
Intervention(s) - The exposure of interest was the use of temporary hip spacer devices during 
the first stage procedure. No preference was given to a device type or to the use of antibiotic-
loaded cement in the spacer.  
Comparator(s) - The results of surgery in the intervention group were compared against patients 
in whom no temporary spacer device was implanted during the first stage. Studies in which other 
non-mechanical constructs, such as antibiotic cement beads, were used in place of spacers were 
also included, as it was anticipated that such an approach would function in a manner like the 
Girdlestone hip.  
Outcome(s) of interest – Studies were sought that reported functional outcomes in the two 
groups of patients during the treatment period and/or following the completion of the second 
stage, the successful eradication of hip infection, as well as the technical difficulties encountered 
during the surgery and perioperative period.  
Study design(s) to be included – No limitations on type of study design were imposed. However, 
only studies that directly compared the two treatment strategies, i.e. use and non-use of hip 
spacers, and the subsequent outcomes of interest in the two groups of patients were included. 
This was done with the aim to ensure results were compared among similar patient populations, 
research strategies and similar outcomes of interest.  Additionally, no time limit was imposed 
upon studies for selection. Only studies published in peer reviewed journals were included.  
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Exclusion Criteria for Studies 
The following studies were excluded: (i) studies reporting outcomes of single-stage revision hip 
arthroplasty, or two-stage revision surgery for indications other than prosthetic hip infections; 
and (ii) studies comparing different types of hip spacer devices in revision hip arthroplasty.  
Search Strategy 
Two independent investigators (AK & IG) were involved in searching for relevant articles that 
fulfilled the inclusion criteria for the study. These were sought out within MEDLINE (Medical 
Literature Analysis and Retrieval System Online), PubMed, CINAHL (Cumulative Index to Nursing 
and Allied Health Literature) and EMBASE (Excerpta Medica dataBASE) search engines. The 
keywords “arthroplasty, replacement, hip”, “two-stage” and “spacer” or “hip spacer” were used 
while searching databases. No search limits, including date or language restrictions, were 
applied to the search strategy (Appendix 1). Relevant grey literature was searched for by using 
the search engine portals ‘Opengrey’ and ‘Google Scholar’. Further, the PubMed “related 
articles” feature, as well as the Google Scholar “cited by” feature was used to identify other 
appropriate research articles. The reference lists of relevant papers were checked, and cited 
articles relevant to the study hand-searched and added.  
Review Method 
All relevant titles and abstracts were screened by the two investigators, and studies that satisfied 
the inclusion criteria were identified. Full text versions of the chosen articles were reviewed, and 
following satisfactory quality appraisal, were included in the review. Any disagreement arising 
between the two investigators at any stage during the review process was resolved by 
discussion, with mediation by a third author (BC) when differences remained. One of the articles 
that was included in the review process was in Czech and an interpreter was enlisted to translate 
its contents.  
Quality Assessment 
Critical appraisal of the selected articles was carried out using the relevant Critical Appraisal 
Skills Programme (CASP) checklists15,16.  
Data Extraction and Outcome Measures  
A bespoke data extraction form, designed by two investigators (AK and IG), was used to collect 
data on objective measures of: (i) functional outcomes during and after treatment; (ii) control 
or eradication of infection; and (iii) technical ease or difficulties encountered during treatment 
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in the two patient groups within the review studies. The chief outcome measures described by 
the review articles included: 
Harris Hip Score (HHS)17 
The HHS is an outcome measure frequently used for the assessment of post-operative hip 
function. It is made up of four subscales – (severity of) pain, function (daily activities and gait), 
(absence of) deformity, and range of motion. Each subscale is awarded points guided by a 
questionnaire as based on patient response, with a score range of 0-100, with higher scores 
denoting better hip function. 
Merle d'Aubigné and Postel Hip Score18 
The Merle d’Aubigne and Postel score is an outcome measure for hip function, and includes the 
parameters pain, mobility, and ability to walk. Each response is rated from 0 to 6 points, with 0 
denoting the worst and 6 denoting the best.   
Western Ontario and McMaster Universities Arthritis Index (WOMAC)19 
The WOMAC is used for the evaluation of hip and knee function. It consists of a questionnaire 
assessing 24 parameters divided over three primary subscales – pain, stiffness and physical 
function. The answers are scored on a scale of 0-4, with higher scores denoting worse outcomes. 
Visual analogue scale (VAS)20 
The VAS is a measurement device used to measure a characteristic or response that is subjective 
and often difficult to measure directly. It is frequently used to assess pain. In its simplest form, 
it asks patients to indicate their pain intensity as a point on a straight line, where the left limit 
of the line denotes worst pain and the right limit denotes best or no pain.  
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)  
The ESR is a non-specific measure of inflammation in the human body. It measures the rate of 
sedimentation of red blood cells in a sample of anticoagulated blood within a thin-walled 
haematology glass tube. Faster sedimentation rates are encountered in the presence of an 
inflammatory response in the body, and by monitoring these rates over a period of time, it is 
possible to assess the control or eradication of infection. 
CRP is an acute phase reactant produced by the liver in response to acute inflammation in the 
human body. In general, CRP levels of above 10 milligrams per litre of blood are considered to 
be indicative of a significant inflammatory response. Similar to ESR, serial CRP levels can be 
monitored to assess the progress or resolution of infection. 
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Criteria for successful THR reimplantation according to Tsukayama et al.21 
Based on their experiences in treating 106 infections in 96 hips that had undergone THR, 
Tsukayama et al.21 defined five criteria for denoting successful eradication of infection in those 
hips. These criteria were: a) a functional hip joint, b) non-painful or minimally painful hip joint 
when walking, c) X-ray findings denoting no signs of loosening or other signs of infection, d) a 
minimum time interval of 24 months since the procedure, and e) no clinical signs of infection in 
the hip. Each criterion had to be met for successful infection eradication to be established.  
Data Analysis 
Data from each paper was extracted onto a separate form and these were created, maintained 
and stored electronically. Considering the small number of studies included in the final review 
and the non-uniform nature of reporting results in each study, the decision was made to present 
the results as a narrative synthesis. However, where possible, trends have been identified and 
reported within each outcome. 
Results 
Search Results 
A total of 123 papers were identified following the use of the outlined search strategy, while a 
further two papers were identified through other sources. Following removal of duplicate 
records, 120 papers were available for screening; of these, 116 were excluded following review 
of title and abstract. The key reasons for exclusion were the reporting of outcomes of a single 
treatment strategy only (spacer or non-spacer) or comparing outcomes between different types 
of spacers within two-stage revision hip arthroplasty, and the reporting of treatment strategies 
not relevant to the review, such as partial implant retention in two-stage exchange, and one-
stage revision arthroplasty. Only four studies were identified that satisfied the inclusion criteria 
for this systematic review22-25. Full-text reports of these four studies were then obtained. All four 
full-text articles were deemed fit for inclusion in the systematic review after quality appraisal 
and eligibility checks conducted by both investigators (AK and IG). A summary of the literature 




Figure 1: Flow diagram summarizing the literature search and screening process 
Study Characteristics 
The four studies were published between the years 2003 and 2016 and comprised a total of 353 
patients treated for late prosthetic hip infection with two-stage revision hip arthroplasty. There 
was a considerably higher proportion of male patients (n=231) compared to female patients 
(n=122). The mean age of the review population was 61.9 years, with the youngest patient of 
age 16 and the oldest of age 90 years.  
170 patients were included in the intervention group and treated with the use of temporary hip 
spacer during the first stage surgery. Different types of spacer devices were employed in the 
studies. One study reported the use of custom articulated spacer with incorporated antibiotic-
loaded bone cement23; two reported the use of cemented monoblock spacer (antibiotic-
loaded)22,25, while the fourth reported the use of a commercially available antibiotic-loaded 
unipolar spacer device that was implanted without the use of bone cement19.  
The overall population included in the control group and treated without hip spacer was 183. In 
one study23, antibiotic-loaded cement beads were used to fill the dead space created after the 
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resection arthroplasty. Both groups of patients, intervention and control, were planned for 
reimplantation of definitive hip prosthesis during the second stage surgery. 
Patients across both groups were followed up for a mean duration of 57.8 months (range 24 – 
128 months). All four studies assessed patients in terms of functional outcome and recurrence 
of infection, while radiographic assessment was formally carried out in two studies22,23. Of the 
four studies included in the review, three were retrospective cohort studies22,23,24, while one was 
a randomized controlled trial (RCT).25 
Assessment of Study Quality 
Quality assessment was undertaken using the relevant Critical Appraisal Skills Programme 
checklists for cohort studies and randomised controlled trials15,16. Although each study included 
in the review had unique methodological strengths and weaknesses (Tables 1 and 2), they 
managed to satisfy the overall requirements for eligibility for inclusion within the review. All four 
studies addressed a clearly focused clinical problem and provided reproducible research 
methods as well as objective measurements of outcomes for both patient groups. 
Table 1: Summary of CASP quality assessment of cohort studies15 
Checklist questions  Marczak et al.24 Hsieh et al.23 Jahoda et al.22 
Section A: Are the results of the study valid 
1. Did the study address a clearly focused issue? Y Y Y 
2. Was the cohort recruited in an acceptable way? Y Y CT 
3. Was the exposure accurately measured to 
minimise bias? 
Y Y Y 
4. Was the outcome accurately measured to 
minimise bias? 
Y Y CT 
5(a) Have the authors identified all important 
confounding factors? 
CT CT CT 
5(b) Have they taken account of the confounding 
factors in the design and/or analysis? 
N CT N 
6(a) Was the follow up of subjects complete enough? Y Y Y 
6(b) Was the follow up of subjects long enough? Y Y Y 
Section B: What are the results? 
7. What are the results of this study? ST ST ST 
8. How precise are the results? SR SR SR 
9. Do you believe the results? Y Y Y 
Section C: Will the results help locally? 
10. Can the results be applied to the local population? CT CT CT 
11. Do the results of this study fit with other 
available evidence? 
N Y Y 
12. What are the implications of this study for 
practice? 
CT Y CT 
Key: CASP, Critical Appraisal Skills Programme; Y, Yes; N, No; CT, Can’t tell; SR, Sufficiently robust; ST, See text – Results 
 
Table 2: Summary of CASP quality assessment of Randomized Controlled Trial16 
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Checklist questions  Cabrita et al.25 
Section A: Are the results of the study valid? 
1. Did the trial address a clearly focused issue? Y 
2. Was the assignment of patients to treatments randomised? Y 
3. Were all of the patients who entered the trial properly accounted for at its conclusion? N 
4. Were patients, health workers and study personnel ‘blind’ to treatment? CT 
5. Were the groups similar at the start of the trial? CT 
6. Aside from the experimental intervention, were the groups treated equally? Y 
Section B: What are the results? 
7. How large was the treatment effect? ST 
8. How precise was the estimate of the treatment effect? SR 
Section C: Will the results help locally? 
9. Can the results be applied to the local population, or in your context? CT 
10. Were all clinically important outcomes considered? Y 
11. Are the benefits worth the harms and costs? CT 
Key: CASP, Critical Appraisal Skills Programme; Y, Yes; N, No; CT, Can’t tell; SR, Sufficiently robust; ST, See text – Results 
Functional Outcome  
All four studies reported an overall improvement in primary hip score results from initial 
assessment to final follow-up in both groups of patients; this improvement was comparatively 
more in the treatment group. Using the Harris Hip Score (HHS)17, Marczak et al.24 reported an 
improvement in hip function by an average of 10.1 points in the interim period following the 
first-stage operation, and by 25.2 points after prostheses replantation, in the treatment group. 
In contrast, the HHS dropped by a mean of 2.6 points in the interim period in the control group, 
while it improved to an overall increase by 16.6 points after the second-stage surgery. The 
difference in HHS between the two groups of patients at both periods in treatment was reported 
as statistically significant (P-value >0.0001, and 0.0005). Hsieh et al.23 used the Merle d'Aubigné 
and Postel Hip Score18 to report improved hip scores from a mean of 8.1 to 13.3 in the interim 
period, and to 15.8 at final follow-up in the treatment group; in the control group, scores at 
similar points in time were noted as 7.9, 10.2 and 15.3 respectively. The difference between the 
hip scores of the two groups in the interim period was deemed statistically significant (P-value 
<0.05). Additionally, their study also reported better mobility among treatment group patients 
during the interim period. 
Marczak et al.24 also reported a statistically significant improvement in WOMAC (Western 
Ontario and McMaster Universities Arthritis Index) score19 in the treatment group in the 
interim period (mean improvement of 5.8 points against -4.0 points; P-value 0.000001). The 
control group was, however reported to have a statistically significant lower VAS (Visual 
analogue scale) score20 during the interim period (mean of 4.0 points against 5.2 points; P-value 
0.0006). A summary of the trends in hip scores across two review studies at the three stages of 
treatment is presented in Figure 2. Cabrita et al.25 reported less treatment related mortality, 
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final leg length discrepancy, and a statistically significant higher percentage of good results 
(81.5% versus 60.0%; P-value<0.001) in the treatment group (Figure 3). 
 
Figure 2: Trends in hip scores across two review studies 
 
Figure 3: Comparison of functional outcomes among control and treatment groups at final 
follow-up in one study (Cabrita et al.25) 
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Eradication of Infection 
Three studies reported better infection control with the use of spacer during first stage surgery 
(Figure 4). This difference was statistically significant in one study25 (P-value 0.002). Three of the 
review studies used serial testing for various markers of inflammation, namely erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP) and white blood cell (WBC) counts, as well as 
subjective clinical and radiological signs to help determine eradication of infection among their 
patients23,24,25. Among these studies, Marczak et al.24 reported recurrence of infection in six 
(12.8%) patients from the spacer group and three (6.4%) patients from the non-spacer group, 
while Hsieh et al.23 reported complete infection control in 56 of 58 patients (96.6%) in the 
treatment group and 66 of 70 patients (94.3%) in the control group at final follow up. Cabrita et 
al.25 also utilised microbiological culture results from intra-articular fluid samples to determine 
correct timing of prosthesis replantation. They reported a significantly higher failed infection 
cure rate of 33.3% in the control group, compared to 10.5% in the treatment group patients. 
Jahoda et al.22 reported 96.5% and 94.3% infection cure rates in the intervention and control 
groups respectively. They used the criteria laid down by Tsukayama et al.21 to define successful 
eradication of infection after treatment. 
Technical Difficulties and Complications 
In three studies, the duration of the second stage procedure was reported to be significantly 
greater in the control group23,24,25. In the study by Cabrita et al.25, the mean duration of hospital 
stay after the first-stage surgery was 24.7 days in the treatment group against 34.6 days in the 
control group (P-value <0.001). Likewise, Hsieh et al.23 reported a mean hospital stay of 18.3 
days versus 24.8 days in the spacer and non-spacer groups respectively (P-value <0.001). The 
reduction in mean duration of hospital stay in the treatment group reported by both these 
studies was statistically significant. In addition, Cabrita et al.25 reported a shorter mean hospital 
stay of 8.2 days in the treatment group against 11.7 days in the control group, as well as a shorter 
mean stay in the intensive care unit of 1.4 days in the treatment group against 4.1 days in the 
control group, after the second stage procedure. Both these differences between the two 
groups were statistically significant (P-value 0.004 for both). 
One study reported a mean blood loss of 952 millilitres and a mean of 1.4 units of blood 
transfused during the procedure in the treatment group, compared to a mean blood loss of 2033 
millilitres and a mean of 3.7 units of blood transfused in the control group23. This reduction in 
intra-operative blood loss and requirement for blood transfusion in the treatment group was 
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statistically significant (P-value <0.001 for both). Cabrita et al.25 also reported statistically 
significant lower volume of fluid drained after each stage surgery in the spacer group (P-value 
0.007 for first stage, 0.01 for second stage).  
Hsieh et al.23 divided the complications encountered among their patients into early and late, 
depending on whether these occurred during the interim period or after final revision 
respectively. Early complications encountered in the control group included hematoma and 
delayed wound healing in three patients, sacral pressure sores in two patients, and femoral 
fracture at the time of replantation and a temporary peroneal nerve palsy in one patient each. 
Nine patients in the control group had postoperative dislocation after definitive revision surgery. 
In the treatment group, two patients had dislocation of the spacer, while another two had 
fracture of the cement spacer. All these patients were managed non-operatively and underwent 
early second stage procedure. One patient had prosthetic dislocation in the treatment group 
after second stage surgery. Six cases of spacer subluxation were reported by Jahoda et al.22, 
while Marczak et al.24 reported one case of spacer subluxation that did not require operative 
intervention and underwent planned second stage revision. Jahoda et al.22 reported two cases 
of postoperative dislocation after the second stage procedure in the control and treatment 
group each. Cabrita et al.25 reported the death of three patients in the control group during the 
study; of them, one patient died from septicemia after the first stage, while two patients died 
due to hemorrhagic complications after the second stage surgery. In the treatment group, one 
patient died due to internal injuries resulting from pelvic migration of the spacer. Three cases of 
spacer dislocation and one case of spacer fracture was reported. A summary of the chief 




Figure 4: Overall number of patients with recurrence of infection in treatment and control 








All four review studies reported better functional outcome at final follow-up after completion 
of treatment in the spacer group. The average increase in HHS across three review studies from 
before initiation of treatment to final follow-up was 36.2 points. Two review studies also 
reported significantly improved function in the spacer group during the interim period. This is 
comparable to other reports published in literature, including Haddad et al.26 who showed an 
improvement in mean HHS from 34 points before treatment to 56 points during the spacer 
stage, and Chalmers et al.27, who reported a rise in mean HHS from 58 to 71 points before and 
after spacer implantation; both these studies had retrospectively assessed two-stage revision 
hip arthroplasty for prosthetic hip infections. In their prospective study on assessing the 
outcome of preformed gentamicin spacers in two-stage revision hip arthroplasty, Pattyn et al.28 
reported that 46 out of 61 patients (75.4%) were able to get discharged from hospital in between 
the two stages. Likewise, in their systematic review of studies on antibiotic-loaded spacers in 
prosthetic hip infection, Anagnostakos et al.29 reported that spacer implantation allowed 
patients to mobilize early after the operation and thereby paved the way for early recovery and 
discharge from hospital.  
Within this review, Hsieh et. al23 also reported that 51 out of 63 patients treated without spacers 
in their study were unable to walk in the interim period. These findings correlate with reports in 
literature that attribute leg shortening and hip instability following a resection arthroplasty to 
causing problems with mobility2. Hsieh et al.23 also reported better outcomes in the interim 
period using custom-made articulated spacers. This is worth noting as the use of an articulating 
spacer has been further reported to improve hip mobility and reduce pain during the interim 
period while awaiting second stage surgery4,30,31. 
The overall infection cure rate across the four studies at the completion of treatment was 92.4% 
in the spacer group against 87.2% in the non-spacer group. Only Marczak et al.24 reported a 
higher infection recurrence rate in the spacer group compared to the non-spacer group, 
although this difference was not statistically significant. Elsewhere in the wider literature, 
similarly reliable infection control rates with spacer use have been reported. Chalmers et al.27 
reported 92% and 88% rate of infection-free prosthesis survivorship after reimplantation at two- 
and five-years follow-up respectively, following two-stage revision hip arthroplasty for 
prosthetic infection treated with antibiotic-loaded spacer. Likewise, Biring et al.32 reported 
infection cure rates of 96% at a mean follow-up of twelve years among 99 patients treated for 
chronically infected hip prosthesis with two-stage revision surgery using antibiotic-impregnated 
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PROSTALAC (prosthesis of antibiotic-loaded acrylic cement) spacers. Better infection control 
with spacer use could be explained by the incorporation of thermostable antibiotics mixed with 
bone cement and used as part of the spacer frame, which has been shown to generate high local 
anti-microbial concentrations within the hip joint33,34.  
The overall incidence of prosthetic dislocation in the control group across the four studies was 
6.5%. Similarly, other studies have also reported prosthetic dislocation to be the most commonly 
encountered complication following reimplantation of total hip prosthesis after Girdlestone 
arthroplasty8,35.  Within this review, surgeons were unable to attempt prosthetic reimplantation 
in three patients in the non-spacer group (1.6%). The technical difficulties encountered by 
surgeons during the second stage in surgeries without a spacer, where it is often difficult to 
identify bony landmarks and dissect soft tissue planes, has led to other documented failures of 
reimplantation as well8,36.  
In the treatment group, a subluxation or dislocation of the spacer was the most commonly 
recurring complication (overall incidence 7.1% across the four studies), followed by spacer 
fracture (1.8%) and intra-pelvic migration of the device (1.2%); in one patient, this resulted in 
injury to the iliac blood vessels and subsequent death of the patient. In the wider literature, 
incidence rates of spacer migration have not been extensively documented. Jung et al. reported 
one case of spacer protrusion out of 88 hip spacer implantations (1.1%)11. It is worth mentioning 
that within the review, Cabrita et. al25 attributed the unipolar nature of the spacer and the 
presence of pre-existing acetabular weakness in the patient as the cause behind the spacer 
migration. They recommended the use of articulated spacers in patients with acetabular bone 
weakness to avoid this complication. Elsewhere in literature, Shen et al.37 have also implicated 
unipolar cement spacers in a deficient acetabulum to be a causative factor, while Jung et al.11 
have also advocated the use of articulated hip spacers to prevent such disastrous pelvic 
migration. 
None of the review studies reported spacer subluxation or fracture as causing any significant 
functional impairment, and no patient required additional surgery from it. Within the studies 
reviewed, the causes of spacer dislocations and fractures were not discussed. Interestingly, 
Jahoda et al.22 reported one case where the decision to implant a spacer had to be abandoned 
during the operation itself, and a resection arthroplasty was instead performed due to the 
presence of extensive acetabular bone defects. In another study within the review, Marczak et 
al.24 clearly state that the surgeons in their study decided not to use spacers in those patients 
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with poor acetabular bone stock, and they attribute this caveat to be responsible for the lower 
rate of spacer-related mechanical complications encountered in their results. A similar message 
has also been conveyed in the wider literature, where researchers have advocated the use of 
resection arthroplasty if spacer use is contraindicated due to factors such as severe acetabular 
bone loss, patient non-compliance or muscular imbalance38.  
The use of articulated spacers was reported by one study within the review23. This was in the 
form of a custom-made antibiotic-loaded cement spacer with three or more large Kirschner 
wires placed inside the femoral component as endoskeleton and employing a cement-on-
cement articulation. The authors considered this method to be simple, inexpensive and easily 
reproducible. Because the spacer was fixed to bone using manual cementing, they believed that 
the use of these spacers could be generalized across various sizes. Elsewhere in literature, similar 
reports on the greater financial viability and generalizability of custom-made articulated cement 
spacers are available38. Other studies in literature have reported the use of prefabricated mobile 
spacers such as the PROSTALAC system and their advantages over custom-made spacers, such 
as less risk of spacer fractures, more consistent antibiotic dosing and elution and reduced 
operative time spent in assembling the spacer construct5,30. A cost versus benefit analysis for 
the use of either articulated spacer variant has not been reported within this review, or 
elsewhere in literature.  
The overall incidence of spacer retention in the review was 5.8%. The cause behind spacer 
retention was not specified. In other reported cases of spacer retention in literature, this has 
been attributed to recurring infection, poor patient health or unwillingness of the patient to 
undergo another operation39. While the effects of prolonged spacer retention on patient health 
and hip function was not reported within the review, other published studies on retained 
spacers within the hip have shown satisfactory outcomes39,40. In particular, based on good hip 
function scores following the use of PROSTALAC spacers, Scharfenberger et al.41 have suggested 
its suitability for long-term retention, if required. More detailed reporting of spacer retention in 
future studies and papers would be helpful in determining its impact on patient outcomes.  
Strengths and Limitations  
As far as the authors are aware, this is the first systematic review to be conducted comparing 
the treatment outcomes following the use or non-use of temporary spacer devices in two-stage 
revision hip arthroplasty for prosthetic hip infection. This study has employed a robust 
methodology as guided by the PRISMA checklist13 to ensure conformity to review protocol 
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throughout. Comparisons across matching populations and treatment protocols within each 
study has been undertaken, thereby increasing the validity of the results. The review has been 
able to generate trends in study outcomes from among the results and thereby satisfy the study 
objectives. The chief limitation of this review is the small number of studies that could be 
included. However, this can be attributed to a scarcity of relevant available literature that 
satisfies the inclusion criteria. Another limiting factor is the fact that the included studies 
differed in methodological structure. These factors have limited the review analysis to a 
narrative synthesis. 
Implications for Future Research and Practice 
Based on the findings of this study the following recommendations can be made: 
1. Based on the limited evidence available, the use of articulated hip spacer constructs with 
antibiotic-loaded bone cement incorporated in the spacer should be considered while 
performing the first stage of two-stage revision hip arthroplasty for prosthetic hip infection.  
2. The benefits of a retrospective study design with consecutive sampling, where the surgeon 
and assessor are both blinded to study objectives, suggest that this is an appropriate design 
for future studies.  
3. National or regional surveys should be conducted among hip surgeons to identify how many 
of them are confident and well-versed in the use of articulated hip spacer constructs or 
require to be further trained in this regard.  
4. Studies on cost versus benefit analysis on commercially available articulated spacers should 
be undertaken to create evidence to support (or not) their regular use. 
5. Studies on custom-made spacer constructs could be undertaken to determine their 
relevance as alternatives to commercially available prefabricated spacers.  
Conclusion  
This systematic review has demonstrated that better functional outcomes occur with the use of 
temporary spacer devices when used during the first stage of a planned two-stage revision hip 
arthroplasty for prosthetic hip infection, compared to the non-use of spacers. The use of spacers 
allows patients to ambulate early after the first stage operation, facilitates early discharge from 
hospital and provides better overall hip function at the end of treatment. The risks of increased 
blood loss during the prosthetic reimplantation, and of post-operative dislocation are 
significantly lowered with spacer use. The use of antibiotic-loaded cement in the spacer 
construct enables good, sustained infection control rates not less than that offered by a 
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resection arthroplasty during the interim period. Articulated spacers such as PROSTALAC and 
other custom-made, cost-effective constructs provide better function, improved spacer 
longevity and reduce risk of intra-pelvic spacer migration. Their use could also allow spacers to 
be retained in unforeseen circumstances when a second surgery for prosthetic reimplantation 
is no longer feasible or desired. However, in certain situations where spacer use is 
contraindicated by patient non-compliance, severe acetabular or femoral bone deficiency or 
muscular imbalance, performing a resection arthroplasty is still the most reasonable option. 
References 
1. Hanssen AD, Osmon DR. Evaluation of a staging system for infected hip arthroplasty. Clin 
Orthop Relat Res, 2002, 403: 16-22. 
2. Fink B. Revision of late periprosthetic infections of total hip endoprostheses: pros and cons 
of different concepts. Int J Med Sci, 2009, 6: 287-295. 
3. Girdlestone GR. Acute pyogenic arthritis of the hip: an operation giving free access and 
effective drainage. Lancet, 1943, 241: 419-421. 
4. Takahira N, Itoman M, Higashi K, Uchiyama K, Miyabe M, Naruse K. Treatment outcome of 
two-stage revision total hip arthroplasty for infected hip arthroplasty using antibiotic-
impregnated cement spacer. J Orthop Sci, 2003, 8: 26-31. 
5. Sukeik M, Haddad FS. Two-stage procedure in the treatment of late chronic hip infections - 
spacer implantation. Int J Med Sci, 2009, 6: 253. 
6. Bertazzoni Minelli E, Benini A, Magnan B, Bartolozzi P. Release of gentamicin and 
vancomycin from temporary human hip spacers in two-stage revision of infected 
arthroplasty. J Antimicrob Chemother, 2004, 53: 329-334. 
7. Burnett RS, Kelly MA, Hanssen AD, Barrack RL. Technique and timing of two-stage exchange 
for infection in TKA. Clin Orthop Relat Res, 2007, 464: 164-178. 
8. Charlton WP, Hozack WJ, Teloken MA, Rao R, Bissett GA. Complications associated with 
reimplantation after girdlestone arthroplasty. Clin Orthop Relat Res, 2003, 407: 119-126. 
9. Macheras GA, Koutsostathis SD, Kateros K, Papadakis S, Anastasopoulos P. A two stage re-
implantation protocol for the treatment of deep periprosthetic hip infection. Mid to long-
term results. Hip Int, 2012, 22: 54-61.  
10. Leunig M, Chosa E, Speck M, Ganz R. A cement spacer for two-stage revision of infected 
implants of the hip joint. Int Orthop, 1998, 22: 209-214. 
11. Jung J, Schmid NV, Kelm J, Schmitt E, Anagnostakos K. Complications after spacer 
implantation in the treatment of hip joint infections. Int J Med Sci, 2009, 6: 265. 
12. Disch AC, Matziolis G, Perka C. Two-stage operative strategy without local antibiotic 
treatment for infected hip arthroplasty: clinical and radiological outcome. Arch Orthop 
Trauma Surg, 2007, 127: 691-697. 
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews 
and meta-analyses: the PRISMA statement. Int J Surg, 2010, 8: 336-341. 
14. O’Connor D, Green S, Higgins JPT. Defining the review question and developing criteria for 
including studies. In: Higgins JPT and Green S. Cochrane Handbook for Systematic Reviews 
of Interventions. Chichester (UK): John Wiley & Sons, 2008. 
15. Critical Appraisal Skills Programme. CASP Cohort Checklist, www.casp-uk.net. (2018, 
accessed 31 July 2019). 
16. Critical Appraisal Skills Programme. CASP Randomized Control Trial Checklist, www.casp-
uk.net. (2018, accessed 31 July 2019). 
 19 
17. Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: an end-
result study using a new method of result evaluation. J Bone Joint Surg [Am], 1969, 51: 737-
755. 
18. d’Aubigne RM, Postel M. Functional results of hip arthroplasty with acrylic prosthesis. J Bone 
Joint Surg [Am], 1954, 35: 451-475. 
19. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: 
a health status instrument for measuring clinically important patient relevant outcomes to 
antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol, 
1988, 15: 1833-1840. 
20. Crichton N. Visual analogue scale (VAS). J Clin Nurs, 2001, 10: 706. 
21. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the 
treatment of one hundred and six infections. J Bone Joint Surg [Am], 1996, 78: 512-523. 
22. Jahoda D, Sosna A, Landor I, Vavrik P, Pokorný D, Hudec T. Two-stage reimplantation using 
spacers - the method of choice in treatment of hip joint prosthesis-related infections. 
Comparison with methods used from 1979 to 1998. Acta Chir Orthop Traumatol Cech, 2003, 
70: 17-24.  
23. Hsieh PH, Shih CH, Chang YH, Lee MS, Shih HN, Yang WE. Two-stage revision hip arthroplasty 
for infection: comparison between the interim use of antibiotic-loaded cement beads and a 
spacer prosthesis. J Bone Joint Surg [Am], 2004, 86: 1989-1997.  
24. Marczak D, Synder M, Sibiński M, Polguj M, Dudka J, Kowalczewski J. Two stage revision hip 
arthroplasty in periprosthetic joint infection. Comparison study: with or without the use of 
a spacer. Int Orthop, 2017, 41: 2253-2258.  
25. Cabrita HB, Croci AT, Camargo OP, Lima AL. Prospective study of the treatment of infected 
hip arthroplasties with or without the use of an antibiotic-loaded cement spacer. Clinics, 
2007, 62: 99-108. 
26. Haddad FS, Masri BA, Garbuz DS, Duncan CP. The treatment of the infected hip replacement: 
the complex case. Clin Orthop Relat Res, 1999, 369: 144-156. 
27. Chalmers BP, Mabry TM, Abdel MP, Berry DJ, Hanssen AD, Perry KI. Two-stage revision total 
hip arthroplasty with a specific articulating antibiotic spacer design: reliable periprosthetic 
joint infection eradication and functional improvement. J Arthroplasty, 2018, 33: 3746-3753.  
28. Pattyn C, De Geest T, Ackerman P, Audenaert E. Preformed gentamicin spacers in two-stage 
revision hip arthroplasty: functional results and complications. Int Orthop, 2011, 35: 1471-
1476. 
29. Anagnostakos K, Fürst O, Kelm J. Antibiotic-impregnated PMMA hip spacers: current status. 
Acta Orthop, 2006, 77: 628-637. 
30. Duncan CP, Beauchamp C. A temporary antibiotic-loaded joint replacement system for 
management of complex infections involving the hip. Orthop Clin North Am, 1993, 24: 751-
759. 
31. Koo KH, Yang JW, Cho SH, et al. Impregnation of vancomycin, gentamicin, and cefotaxime in 
a cement spacer for two-stage cementless reconstruction in infected total hip arthroplasty. 
J Arthroplasty, 2001, 16: 882-892. 
32. Biring GS, Kostamo T, Garbuz DS, Masri BA, Duncan CP. Two-stage revision arthroplasty of 
the hip for infection using an interim articulated Prostalac hip spacer: a 10-to 15-year follow-
up study. J Bone Joint Surg [Br], 2009, 91: 1431-1437. 
33. Masri BA, Duncan CP, Beauchamp CP. Long-term elution of antibiotics from bone-cement: 
an in vivo study using the prosthesis of antibiotic-loaded acrylic cement (PROSTALAC) 
system. J Arthroplasty, 1998, 13: 331-338. 
34. Isiklar ZU, Demirörs H, Akpinar S, Tandogan RN, Alparslan M. Two-stage treatment of chronic 
staphylococcal orthopaedic implant-related infections using vancomycin impregnated 
 20 
PMMA spacer and rifampicin containing antibiotic protocol. Bull Hosp Jt Dis, 1999, 58: 79-
85.  
35. Ikebe S, Sonohata M, Kitajima M, Kawano S, Mawatari M. Total hip arthroplasty following 
Girdlestone arthroplasty. J Orthop Sci, 2018, 23: 532-537. 
36. Fitzgerald Jr RH. Total hip arthroplasty sepsis. Prevention and diagnosis. Orthop Clin North 
Am, 1992, 23: 259-264. 
37. Shen DL, Yu CT, Chang IL, Chen SJ. Iliac vessel injury by a cement spacer: report of a case. Int 
Surg, 2007, 92: 78-81. 
38. Anagnostakos K, Jung J, Schmid NV, Schmitt E, Kelm J. Mechanical complications and 
reconstruction strategies at the site of hip spacer implantation. Int J Med Sci, 2009, 6: 274. 
39. Choi HR, Freiberg AA, Malchau H, Rubash HE, Kwon YM. The fate of unplanned retention of 
prosthetic articulating spacers for infected total hip and total knee arthroplasty. J 
Arthroplasty, 2014, 29: 690-693. 
40. Hofmann AA, Goldberg TD, Tanner AM, Cook TM. Ten-year experience using an articulating 
antibiotic cement hip spacer for the treatment of chronically infected total hip. J 
Arthroplasty, 2005, 20: 874-879. 
41. Scharfenberger A, Clark M, Lavoie G, O'Connor G, Masson E, Beaupre L. Treatment of an 
infected total hip replacement with the PROSTALAC system. Part 2: Health-related quality 
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